Form 8-K - Current report:
SEC Accession No. 0000950170-24-124598
Filing Date
2024-11-12
Accepted
2024-11-12 07:40:47
Documents
12
Period of Report
2024-11-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mreo-20241108.htm   iXBRL 8-K 53618
2 EX-99.1 mreo-ex99_1.htm EX-99.1 242160
  Complete submission text file 0000950170-24-124598.txt   480372

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20241108.xsd EX-101.SCH 58315
15 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20241108_htm.xml XML 6696
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38452 | Film No.: 241443362
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)